Methods of treatment for cystic fibrosis

Patent metadata

Field	Value
Publication number	US-12350262-B2
Application number	US-202217899660-A
Country	US
Kind code	B2
Filing date	Aug 31, 2022
Priority date	Jul 17, 2017
Publication date	Jul 8, 2025
Grant date	Jul 8, 2025

Abstract

Compound I of the formulaand/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

First claim

The invention claimed is:

1. A method of treating cystic fibrosis comprising administering to a patient in need thereof:
(a) 200 mg once daily of crystalline Form A of Compound I:

(b) 100 mg once daily of amorphous Compound II:

 and
(c) 150 mg per dose twice daily of amorphous Compound III:

2. A method of treating cystic fibrosis comprising administering to a patient in need thereof:
(a) 100 mg once daily of crystalline Form A of Compound I:

(b) 50 mg once daily of amorphous Compound II:

 and
(c) 75 mg per dose twice daily of amorphous Compound III:

3. The method of claim 1 , wherein the method comprises administering 200 mg of Compound I, 100 mg of Compound II, and 150 mg of Compound III; followed by administering 150 mg of Compound III 12 hours later.

4. The method of claim 2 , wherein the method comprises administering 100 mg of Compound I, 50 mg of Compound II, and 75 mg of Compound III; followed by administering 75 mg of Compound III 12 hours later.

Assignees

• Vertex Pharma

Inventors

• Chen Weichao George
• Haseltine Eric L
• Moskowitz Samuel
• Robertson Sarah
• Waltz David

Classifications

• A61K31/443

  containing a five-membered ring with oxygen as a ring hetero atom · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K31/47

  Quinolines; Isoquinolines · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K31/404

  Indoles, e.g. pindolol · CPC title